Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
TMPRSS2 localization and expression was evaluated in 415 cases of primary prostate cancer and 144 prostate cancer metastases by immunohistochemistry.
|
18338334 |
2008 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Altogether, our work indicates that TMPRSS2-ERG increases bone tropism of PCa cells and metastasis development.
|
28055969 |
2017 |
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Cancer cells maintain androgen receptor-regulated cytoplasmic TMPRSS2 expression, which facilitates EMT invasion and metastasis in model systems through hepatocyte growth factor and c-MET signaling.
|
25367948 |
2014 |
Neoplasm Metastasis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Concordance in TMPRSS2-ERG status between primary tumors and metastases was 70.9% (Kappa 0.39); 20.9% and 8.1% of the patients showed the mutation solely in their primary tumors and metastases, respectively.
|
25252136 |
2014 |
Neoplasm Metastasis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
CTCs were detected in 14 of 15 (93%) patients with metastatic disease (median = 63 CTCs/mL, mean = 386 ± 238 CTCs/mL), and the tumor-specific TMPRSS2-ERG translocation was readily identified following RNA isolation and RT-PCR analysis.
|
20930119 |
2010 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
LHGDN |
Detection of TMPRSS2:ERG fusion gene in circulating prostate cancer cells.
|
18385909 |
2008 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
However, in the univariate Cox analysis, only TMPRSS2-ERG status (hazard ratio [HR] 0.189, 95% CI 0.057-0.629; P = 0.007) and distant metastasis (HR 3.545, 95% CI 1.056-11.894; P = 0.040) were significantly associated with 2-year OS.
|
25973080 |
2015 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In summary, our results establish that TMPRSS2 promotes the growth, invasion, and metastasis of prostate cancer cells via matriptase activation and extracellular matrix disruption, with implications to target these two proteases as a strategy to treat prostate cancer.
|
26018085 |
2015 |
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The TMPRSS2:E‑twenty‑six (ETS) gene fusion occurs frequently in a high proportion of patients with prostate cancer (PCa) in Western countries, and the aberrant expression of TMPRSS2: v‑ETS avian erythroblastosis virus E26 oncogene homolog (ERG), the most common form of the corresponding protein, can regulate cell migration and contribute to tumor invasion and metastasis.
|
26935606 |
2016 |
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
LHGDN |
The present study describes how TMPRSS2 may contribute to prostate tumour metastasis via the activation of PAR-2.
|
15537383 |
2005 |
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The present study describes how TMPRSS2 may contribute to prostate tumour metastasis via the activation of PAR-2.
|
15537383 |
2005 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These findings provide a mechanistic link between TMPRSS2-ERG translocations and intracellular kinase-mediated phosphorylation of ERG on enhanced metastasis of tumor cells via CXCR4 expression and function in prostate cancer cells.
|
23918819 |
2013 |
Neoplasm Metastasis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
We analyzed TMPRSS2-ERG gene rearrangement status by fluorescence in situ hybridization in 521 cases of clinically localized surgically treated prostate cancer with 95 months of median follow-up and also in 40 unmatched metastases.
|
19190343 |
2009 |